Physician profile
Eric Duquella
NPI 1225019896
$1,137.33
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $392 · 2021: $414.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $467.12 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $282.33 | 2019-2021 | |
| Gilead Sciences, INC. | $191.40 | 2020-2021 | |
| Intercept Pharmaceuticals, INC. | $35.27 | 2019-2020 | |
| Pfizer INC. | $29.73 | 2019 | |
| Ironwood Pharmaceuticals, INC | $28.22 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.64 | 2019 | |
| Redhill Biopharma INC. | $19.46 | 2020 | |
| W. L. Gore & Associates, INC. | $14.43 | 2021 | |
| Celgene Corporation | $14.34 | 2021 | |
| Alfasigma USA, INC. | $12.44 | 2020 | |
| Allergan, INC. | $11.95 | 2019 | |
| Nestle Healthcare Nutrition INC. | $11.00 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Duquella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.